Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Primary objective:
To evaluate the response rate of biweekly gemcitabine and oxaliplatin (the GEMOX regimen) in
the first line treatment of metastatic or recurrent nasopharyngeal carcinoma.
Secondary objectives:
To assess the toxicity, duration of response, time to progression, progression-free survival,
overall survival and cancer-related symptoms in the first line treatment of patients with
metastatic or recurrent NPC.